Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory AML or Higher-Risk Myelodysplastic Syndromes
Conditions
Interventions
BST-236
Locations
4
United States
Ochsner LSU Health Shreveport - Academic Medical Center
Shreveport, Louisiana, United States
The University of Texas MD Anderson Cancer center
Houston, Texas, United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Start Date
November 14, 2021
Primary Completion Date
December 14, 2023
Completion Date
March 14, 2024
Last Updated
March 9, 2023
NCT03050268
NCT06656494
NCT06465953
NCT07081087
NCT03520647
NCT06859424
Lead Sponsor
BioSight Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions